S
1.11
0.08 (7.77%)
| Previous Close | 1.03 |
| Open | 1.03 |
| Volume | 108,439 |
| Avg. Volume (3M) | 2,757,000 |
| Market Cap | 2,977,273 |
| Price / Book | 2.14 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -69.25 |
| Total Debt/Equity (MRQ) | 33.61% |
| Current Ratio (MRQ) | 2.78 |
| Operating Cash Flow (TTM) | -8.62 M |
| Levered Free Cash Flow (TTM) | -4.73 M |
| Return on Assets (TTM) | -115.04% |
| Return on Equity (TTM) | -346.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Shuttle Pharmaceuticals Holding | - | - |
AIStockmoo Score
0.1
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.13 |
|
Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 5.82% |
| % Held by Institutions | 0.84% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Jan 2026 | Announcement | Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |